Teligene, a China-based small-molecule oncology therapeutics developer backed by pharmaceutical manufacturer Suzhong Pharma and financial services firm China Construction Bank, has raised RMB600m ($93m) in pre-IPO funding, DealStreetAsia reported yesterday.
Healthcare investor GTJA Investment Group also took part in the round, which followed an undisclosed amount of series B funding from Suzhong Pharma, China Construction Bank’s CCB Capital unit, GTJA, IDG Capital, Shenzhen Capital, Loyal Valley Capital and Huitianfu Capital in 2018.
Founded in 2011, Teligene is developing small-molecule drugs to treat lung, skin, head, neck and breast cancers. The company has five oncology drug candidates in the preclinical stage, according to its website.
Teligene’s largest shareholder is Suzhou Fanglve Biotech with a 21% stake. Its other investors include Shenzhen Capital (7.1%), GTJA (3.3%), Suzhong Pharma (2%) and Loyal Valley Capital (0.1%).